Onsdag 30 Oktober | 09:25:15 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-02-19 08:00 Bokslutskommuniké 2024
2024-11-07 08:00 Kvartalsrapport 2024-Q3
2024-08-27 - Kvartalsrapport 2024-Q2
2024-05-16 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2024-05-15 - Årsstämma
2024-05-03 - Kvartalsrapport 2024-Q1
2024-02-21 - Bokslutskommuniké 2023
2023-11-20 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-06-09 - Årsstämma
2023-05-30 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2023-05-04 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-10-25 - Kvartalsrapport 2022-Q3
2022-08-26 - Kvartalsrapport 2022-Q2
2022-06-10 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2022-06-09 - Årsstämma
2022-04-20 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-10 - Kvartalsrapport 2021-Q3
2021-08-20 - Kvartalsrapport 2021-Q2
2021-05-06 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2021-02-18 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-06-03 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2020-06-02 - Årsstämma
2020-05-15 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2019-11-12 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-06-12 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2019-06-11 - Årsstämma
2019-05-15 - Kvartalsrapport 2019-Q1
2019-02-20 - Bokslutskommuniké 2018
2018-11-12 - Kvartalsrapport 2018-Q3
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-30 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2018-05-29 - Årsstämma
2018-05-15 - Kvartalsrapport 2018-Q1
2018-02-20 - Bokslutskommuniké 2017
2017-11-10 - Kvartalsrapport 2017-Q3
2017-10-23 - Extra Bolagsstämma 2017
2017-08-24 - Kvartalsrapport 2017-Q2
2017-06-13 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2017-06-12 - Årsstämma
2017-05-17 - Kvartalsrapport 2017-Q1
2017-02-15 - Bokslutskommuniké 2016
2016-11-16 - Kvartalsrapport 2016-Q3
2016-08-17 - Kvartalsrapport 2016-Q2
2016-05-27 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2016-05-26 - Årsstämma
2016-05-12 - Kvartalsrapport 2016-Q1
2016-04-06 - Extra Bolagsstämma 2016
2016-02-25 - Bokslutskommuniké 2015
2015-11-19 - Kvartalsrapport 2015-Q3
2015-08-20 - Kvartalsrapport 2015-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Nanexa är ett drug delivery-bolag med en egenutvecklad plattform som används för formulering av injicerbara depåläkemedel som skapar en tillförsel av läkemedel till blodet. PharmaShell processen baseras på ALD (Atomic Layer Deposition) teknologin som innesluter läkemedelspartiklar med ett tunt skal och skapar möjlighet för läkemedelsbolag att utveckla nya produkter. Nanexa har samarbete med flertalet läkemedelsbolag, huvudsakligen runtom den nordiska marknaden.
2024-02-21 08:00:00

NEX-22 clinical trial application submitted, secured funding and tactical priorities for 2024

Significant events during the fourth quarter 2023

  • Nanexa announced the completion of the phase I study NEX-20-01. In addition to previously communicated positive results from the pharmacokinetic evaluation, the company received final safety and tolerability data that also support the further development of the project.
  • Nanexa announced the outcome of the company's rights issue of approximately SEK 121 million, which showed that 42,146,268 shares, corresponding to approximately 34.7 percent of the rights issue, had been subscribed with and without subscription rights. Hence, guarantee commitments of 32,853,732 shares, corresponding to approximately 27.1 percent of the offered shares, were utilized and the rights issue provided the company with SEK 75 million before deduction of transaction costs.
  • Nanexa signed a so-called Material Transfer and Feasibility Study Agreement with one of the largest global pharmaceutical companies, for the evaluation of Nanexa's drug delivery system, PharmaShell®, in a depot formulation of a monoclonal antibody.
  • Nanexa announced that the clinical trial application for the Phase I study of NEX-22 in patients with type 2 diabetes has been received and validated by the European Medicines Agency (EMA).
  • Nanexa's Board of Directors decided to focus the business on three key areas. The decision entails tactical prioritization and cost savings with the aim that the current cash position and expected revenues from evaluation agreements will be sufficient until mid 2025 and enable significant value-creating progress in prioritized collaborations and the proprietary project NEX-22.

Significant events after the end of the period

  • No significant event after the end of the period.

Summary of the reporting period 1 October – 31 December 2023

  • Turnover amounted to: TSEK 6,816 (819)
  • Operating profit (EBIT) amounted to: SEK -51,367 (-17,869)
  • Profit after tax amounted to: TSEK -51,150 (-17,932)
  • Earnings per share amounted to: SEK -0.52 (-0.35)
  • Cash flow for the period amounted to: TSEK 44,599 (35,574)
  • Cash and cash equivalents at end of period: TSEK 65,168 (81,182)

Summary of the reporting period 1 January – 31 December 2023

  • Turnover amounted to: TSEK 29,327 (2,860)
  • Operating profit (EBIT) amounted to: TSEK -76,625 (-57,981)
  • Profit after tax amounted to: TSEK -76,398 (-58,571)
  • Earnings per share amounted to: SEK -1.09 (-1.16)
  • Cash flow for the period amounted to: TSEK -16,014 (-24,478)
  • Cash and cash equivalents at end of period: TSEK 65,168 (81,182)
  • The Board of Directors proposes that no dividend is paid for the fiscal year 2023.

Figures in brackets refer to the corresponding period in the previous year.

The entire report is available on the company’s website: https://nanexa.com/en/financial-reports/.

Report commentary, February 21 at 11:30am CET
A live commentary with CEO David Westberg and CFO Björn Svanström will take place on February 21 at 11:30am via Infront Direkt Studios and viewers will have the opportunity to ask questions via chat. The presentation will be held in Swedish.

The report commentary will be available via this link.
The report comment will also be published on Nanexa's website afterwards.